Transitioning From RUO to cGMP for Clinical Trials

Both RUO and cGMP compliance play important roles in the drug discovery pipeline. However, meeting regulatory demands can be a challenge when accelerating new drugs to the clinic.

Making the transition from RUO to cGMP chemicals as early as possible can have significant benefits including reduced costs, managed risk and faster delivery to market. Hence, it’s essential to partner with suppliers and supply chain management teams that you can trust.

Download this executive summary to:

• Discover how to mitigate risk during your RUO to cGMP transitions
• Access case studies featuring strategies that work for CDMOs
• Explore how you could achieve projected annual savings of up to $207K in operating expenses